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Using older techniques from TALENs and the newer technology
of CRISPR/Cas9, it is possible to assemble an array of guide
RNAs (gRNA) for targeting multiple genes at once with Cas9.
The guide array is assembled using the Golden Gate assembly
method of TALENs. The guide array contains truncated gRNAs
with short regions of target complementarity for CRISPR/Cas9.
This allows for the knockin and knockout of multiple genes
through homologous recombination. A CMV promoter is
included in the vector. In this experiment, we will provide 2
tumor suppressor genes, Rb1 and p53, flanked with 4 gRNAs
each (a total of 8 gRNAs). This array will be conditionally
expressed in mice by integration into a cassette vector.
Thank you to the Moriarity Lab for their direction in this
project. This project was supported by Multiplexed
Conditional Mice project and the University of Minnesota
Undergraduate Research Opportunity (UROP).
• Insert the BFP Puro-TK into the cassette in mouse ES cells
using Flp plasmid
• Confirm successful integration of BFP Puro-TK for further
use as a selective marker
• Exchange the CMV-gRNA array with the BFP/PuroTK
cassette and test for knockdown of Rb1 and p53 genes
• Implant cells into pseudo-pregnant mice and breed/age
for cancer development
Cancer is a genetically heterogeneous disease in which
altered expression of genes result in a disruption in normal
somatic cell growth. Researchers have developed numerous
mouse models of cancer that rapidly and accurately model
the disease. This has largely relied on the generation of
transgenic mice expressing the Cre recombinase system,
which can be used to delete or activate specific genes in a
particular cell/tissue type in the mouse. It is very laborious
and time consuming to generate the Cre-based models of
cancer developing, most requiring the breeding of 3-4
different transgenic models into a single mouse. This barrier
has largely precluded their use for pre-clinical drug testing. To
address this barrier, we plan to utilize the CRISPR/Cas9
nuclease system to delete or activate specific genes that will
produce cancer in the same exact fashion as the Cre-based
models. Critically, we implemented multiplexed CRISPR
gRNAs that can target 10 or more genes at one time, with a
single transgenic mouse. We also targeted CRISPR activity in a
conditional manner, allowing us to target only the cells or
tissues we desire. Using this method, we will be able to
generate experimental mice from a single breeding regardless
of the number of genes to be deleted or activated, removing
the need for laborious and costly breeding schemes to
generate mouse models of cancer based on the Cre system.
We engineered this CRISPR system in mouse embryonic stem
(ES) cells that will be used to generate our multiplexed
conditional CRISPR (MCC) transgenic animals. Subsequent
MCC mice will be bred and aged for tumor development to
validate our system.
A cassete vector including mCherry and dEGFP must be
integrated into the Rosa26 genomic locus of the mouse ES
cell. Rosa26 is a constituitive and ubiquitive locus commonly
used in conditional reporter mouse lines. The Rosa26
cassette includes two FRT sites which allow for the
integration of the vector containing the CMV-gRNA array
previously described. The expression of the guide array will
be checked by PCR and TIDE analysis. Lastly, the iCaspase 9 in
the cassette acts as a kill-switch with non-integrated cells
through the use of a suicide gene system with the small-
molecule drug AP1903. • Mouse ES cells can integrate the Rosa26 Cassette
• Correct integration was confirmed using Cre/LoxP excision
of mCherry and sequencing
• Selection of ES cells using iCaspase9 does not work
• BFP-PuroTK plasmid constructed for cassette exchange
Abstract
Multiplexed guide array through 
Golden Gate assembly
A cassette exchange system to introduce a multiplexed gRNA
array into mouse embryonic stem cells will rapidly produce
transgenic mouse models of cancer.
• Cell culture: ES cells were co-cultured on top of a 
monolayer of mouse embryonic fibroblasts (MEFs). ES 
cells were cultured at 37 degrees C in 5% CO2 in IMDM 
(20% ES cell-qualified FBS, 2mM L-glutamine, 1X non-
essential amino acids, and 0.1 mM B-mercaptoethanol.)
• Cell Transfection: The Neon Transfection System (Thermo
Fisher Scientific) was used to electroporate 1 x 106 million 
MEF-depleted ES cells with 1,400V pulse, 10ms width, 3 
pulses. After electroporation, cells were placed into a 
fresh well of feeder cells on a 24-well plate. 
• Plasmid and vector construction: Plasmids were 
constructed using BP and LR clonase enzymes.
• Flow cytometry: ES cells were MEF-depleted and not 
fixed. Cells were stained with Sytox Blue. They were run 
using a WT ES cell control on a BD LSRFortessa machine.  
All results were analysed using FlowJo.
• Sequencing: All sequencing was done by the UMN 
Genomics Center.
Hypothesis
Conditional expression of guide 
array
Materials & Methods
Integration of Rosa26 cassette
Cre excision of mCherry
BFP/Puro/TK plasmid construction





Flow cytometry assay comparing the expression of eGFP and
mCherry. A. Mouse embryonic stem cells with no Cre excision
enables a double positive expression of eGFP and mCherry
B. Cells with Cre excision are eGFP positive and have reduced
mCherry expression.
Figure 4: Mouse embryonic stem cells express eGFP and
mCherry before and after Cre excision.
Figure 1: CMV-gRNA Array
Figure 2: Rosa26 cassette exchange with CMV-gRNA 
Array using iCaspase9 as a selection for successful 
integration
ES cells transfected with the Rosa26 cassette were B. GFP and 
C. mCherry positive. This confirms the integration of the 
cassette as cells express markers inside and outside of FRT 
sites. 
Figure 3: Mouse embryonic stem cells express GFP and 
mCherry after transfection with Rosa26 cassette
Once cells had a confirmed integration of the Rosa26 cassette,
the iCaspase9 kill switch selection marker was tested by
adding the small molecule drug AP1903 to the cells. After no
change was observed after drug addition, it was concluded
that a new selection marker must be employed through a new
cassette exchange by FRT sites with a BFP/Puro/TK plasmid.
This plasmid was constructed with a PGK promoter.
Figure 5: Cassette 




with the CMV gRNA 
array is illustrated
Figure 6: Transient expression 
of the BFP Puro-TK plasmid in 
HEK293T cells under bright 
field and BFP fluorescence to 
test for correct construction of 
plasmid.  
A/B. 2ug of BFP Puro-TK 
plasmid. C/D: 6ug of BFP 
Puro-TK plasmid E/F: 1ug of 
GFP pmax control
